Up-regulation of Biglycan is Associated with Poor Prognosis and PTEN Deletion in Patients with Prostate Cancer.

doi:10.1016/j.neo.2017.06.003

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Up-regulation of Biglycan is Associated with Poor Prognosis and PTEN Deletion in Patients with Prostate Cancer.

Neoplasia (New York, N.Y.) - 1 Sept 2017

Jacobsen Frank, Kraft Juliane, Schroeder Cornelia, Hube-Magg Claudia, Kluth Martina, Lang Dagmar S, Simon Ronald, Sauter Guido, Izbicki Jakob R, Clauditz Till S, Luebke Andreas M, Hinsch Andrea, Wilczak Waldemar, Wittmer Corinna, Büscheck Franziska, Höflmayer Doris, Minner Sarah, Tsourlakis Maria Christina, Huland Hartwig, Graefen Markus, Budäus Lars, Thederan Imke, Salomon Georg, Schlomm Thorsten, Melling Nathaniel

Abstract excerpt

Biglycan (BGN), a proteoglycan of the extracellular matrix, is included in mRNA signatures for prostate cancer aggressiveness. To understand the impact of BGN on prognosis and its relationship to molecularly defined subsets, we analyzed BGN expression by immunohistochemistry on a tissue microarray containing 12,427 prostate cancers. Seventy-eight percent of 11,050 interpretable cancers showed BGN expression,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Epithelium

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Kaplan-Meier Estimate

Share to Neoplasm Grading

Share to Oncogene Proteins, Fusion

Share to Prostate-Specific Antigen

Share to PTEN Phosphohydrolase

Share to Receptors, Androgen

Share to Transcriptional Regulator ERG

Source

Open in PubMed Open full text

Identifiers

PMID: 28830008
DOI: 10.1016/j.neo.2017.06.003
PMCID: PMC5565634

Genes

BGN
PTEN
ERG

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Up-regulation of Biglycan is Associated with Poor Prognosis and PTEN Deletion in Patients with Prostate Cancer.PMID 28830008Read ↗

Biglycan Overexpression Predicts Poor Prognosis of Gastric CancerSemantic proximity Read ↗

Novel Androgen Receptor Coregulator GRHL2 Exerts Both Oncogenic and Antimetastatic Functions in Prostate CancerSemantic proximity Read ↗

Biglycan Promotes Cancer Stem Cell Properties, NFκB Signaling and Metastatic Potential in Breast Cancer CellsSemantic proximity Read ↗

Inhibition of Stromal Biglycan Promotes Normalization of the Tumor Microenvironment and Enhances Chemotherapeutic EfficacySemantic proximity Read ↗

The Complexity and Dynamics of the Tissue Glycoproteome Associated With Prostate Cancer ProgressionSemantic proximity Read ↗

SFRP4 gene expression is increased in aggressive prostate cancerSemantic proximity Read ↗

Characterization of Transcriptional Changes in ERG Rearrangement-Positive Prostate Cancer Identifies the Regulation of Metabolic Sensors Such as Neuropeptide YSemantic proximity Read ↗

Ankyrin G expression is associated with androgen receptor stability, invasiveness, and lethal outcome in prostate cancer patientsSemantic proximity Read ↗

Functional characterization of three novel candidate biomarkers and therapeutic targets for prostate cancerSemantic proximity Read ↗

Integrative analysis of the ST6GALNAC family identifies GATA2-upregulated ST6GALNAC5 as an adverse prognostic biomarker promoting prostate cancer cell invasionSemantic proximity Read ↗

Microseminoprotein-Beta Expression in Different Stages of Prostate Cancer.Semantic proximity Read ↗

Reduced KLK2 expression is a strong and independent predictor of poor prognosis in ERG-negative prostate cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.